78738-31-5

Upstream product

• 2177-51-7 cis-cyclopropane diisocyanate 
• 696-74-2 cis-1,2-cyclopropanedicarboxylic acid 
• 68979-48-6 r-1,c-2-Cyclopropandicarbonsaeurediazid 
• 58616-95-8 trans-1,2-cyclopropanedicarboxylic acid 
• 1501-56-0 (trans)-cyclopropane-1,2-dicarbonyl dichloride 

Downstream Products

• 3418-55-1 trans-N,N'-Bis(2,4,6-trimethylbenzyliden)-1,2-cyclopropandiamin 
• 87058-74-0 trans-N,N'-Bis<3,5-di(1,1-dimethylethyl)benzyliden>-1,2-cyclopropandiamin 
• 87058-73-9 trans-N,N'-Bis(3,5-dimethylbenzyliden)-1,2-cyclopropandiamin 
• 87058-72-8 trans-N,N'-Bis(4-chlorbenzyliden)-1,2-cyclopropandiamin 
• 733-41-5 trans-N,N'-dibenzylidene-1,2-cyclopropanediamine 
• 731-65-7 cis-2,3-Dihydro-2,3-diphenyl-1H-1,4-diazepine 
• 265987-99-3 (+/-)-(trans)-N-tert-butyloxycarbonyl-1,2-cyclopropanediamine 
• 3187-74-4 trans-N,N'-Bis(4-methylbenzyliden)-1,2-cyclopropandiamin 
• 87058-77-3 cis-2,3-Dihydro-2,3-bis(pentadeuteriophenyl)-1H-1,4-diazepin 

Relevant academic research and scientific papers

Benzamides derived from 1,2-diaminocyclopropane as novel ligands for human D2 and D3 dopamine receptors

Benzamides (3a-f) derived from 4-amino-5-chloro-2-methoxybenzoic acid and either cis or trans 1,2-diaminocyclopropane were synthesised and were evaluated in binding assays employing, bovine striatal D2 receptors, recombinant human hD2/sub

ALKYLBORONIC ACIDS AS ARGINASE INHIBITORS

Provided are alkylboronic acids as arginase inhibitors represented by formula (I), or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof and a pharmaceutical composition comprising said compounds.

An efficient and improved process for the scale-up preparation of cis-cyclopropanediamine dihydrochloride

An effective and improved process for the preparation of cis-cyclopro panediamine dihydrochloride was developed in a 100 g scale. The key step in the process is the preparation of ciscyclopropane-1, 2-dicarboxylic acid from a mixture of cis- and transisomers by the formation of cyclic acidic anhydride. The whole process and all of the procedures are economical, industrially reliable and easily scaled up.

Molecular modelling studies, synthesis and biological activity of a series of novel bisnaphthalimides and their development as new DNA topoisomerase II inhibitors

A series of bisnaphthalimide derivatives were synthesized and evaluated for growth-inhibitory property against HT-29 human colon carcinoma. The N,N′-bis[2-(5-nitro-1,3-dioxo-2,3-dihydro-1H-benz[de]-isoquinolin- 2-yl)]propane-2-ethanediamine (9) and the N,N′-Bis[2-(5-nitro-1,3-dioxo-2,3-dihydro-1H-benz[de]-isoquinolin- 2-yl)]butylaminoethyl]-2-propanediamine (12) derivatives emerged as the most potent compounds of this series. Molecular modelling studies indicated that the high potency of 12, the most cytotoxic compound of the whole series, could be due to larger number of intermolecular interactions and to the best position of the naphthalimido rings, which favours π-π stacking interactions with purine and pyrimidine bases in the DNA active site. Moreover, 12 was designed as a DNA topoisomerase II poison and biochemical studies showed its effect on human DNA topoisomerase II. We then selected the compounds with a significant cytotoxicity for apoptosis assay. Derivative 9 was able to induce significantly apoptosis (40%) at 0.1 μM concentration, and we demonstrated that the effect on apoptosis in HT-29 cells is mediated by caspases activation.

Cyclopropanediamines, 4. - Synthesis and 1H-NMR Spectra of Pure Diastereomers of 1,2-Cyclopropanediamines and 1,2-Cyclopropanediammonium Dibromides

The efficient preparation of pure diastereomers of N,N'-(1,2-cyclopropanediyl)diurethanes 16-18 and -diammonium dibromides 4, 19, and 20 is reported.Curtius rearrangement of cis- and trans-1,2-cyclopropanedicarboxylic dihydrazides 14 yields di(O-benzyl) d